BLA 761289 · Astrazeneca Ab
Imjudo
Tremelimumab-Actl · Intravenous · CTLA-4-directed Blocking Antibody
NovelPriority reviewOrphanCDER novel approval, Oct 21, 2022: To treat unresectable hepatocellular carcinoma
Last checked: Nov 20, 2026Latest source record: Aug 31, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2022
Oct 21, 2022
Approved uses
1
Original approval plus efficacy supplements
Registered trials
260
26 Phase 3, 38 recruiting
FAERS reports
4,428
4,294 serious, 1,275 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 31, 2026.
IMJUDO is a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) blocking antibody indicated: • in combination with durvalumab, for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC). ( 1.1 ) • in combination with durvalumab and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumor aberrations. ( 1.2 ) 1.1 Hepatocellular Carcinoma IMJUDO, in combination with durvalumab, is indicated for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC). 1.2 Non-Small Cell Lung Cancer (NSCLC) IMJUDO, in combination with durvalumab and platinum-based chemotherapy, is indicated for the treatment of adult patients with metastatic NSCLC with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic tumor aberrations.
Mechanism: CTLA-4 is a negative regulator of T-cell activity. Tremelimumab-actl is a monoclonal antibody that binds to CTLA-4 and blocks the interaction with its ligands CD80 and CD86, releasing CTLA-4-mediated inhibition of T-cell activation. In synergistic mouse tumor models, blocking CTLA-4 activity resulted in decreased tumor growth and increased proliferation of T cells in tumors.
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 21, 2022 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelLetterReview
2 products under this application
- IMJUDO · TREMELIMUMAB-ACTL 25MG/1.25ML(20MG/ML) · INJECTABLE, INTRAVENOUS · Prescription
- IMJUDO · TREMELIMUMAB-ACTL 300MG/15ML(20MG/ML) · INJECTABLE, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Tremelimumab" as an intervention, any sponsor and status, largest first.
- Renal Adjuvant MultiPle Arm Randomised TrialPivotal-lookingRecruiting
University College, LondonAcademic, hospital or other
NCT03288532 · 1,750 participants (planned) · Start Jul 19, 2018 · Primary completion Jul 1, 2024
Drug: Durvalumab; Tremelimumab · For: Renal Cell Carcinoma
Sites: Aberdeen, United Kingdom; Bangor, United Kingdom; Bournemouth, United Kingdom · 35 sites in all
- Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular CarcinomaPivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT03298451 · 1,324 participants · Start Oct 11, 2017 · Primary completion Aug 27, 2021
Drug: Durvalumab; Tremelimumab (Regimen 1) and 4 more · For: Hepatocellular Carcinoma
Sites: Los Angeles, California; Orange, California; San Francisco, California · 160 sites in all
- Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial CancerPivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT03682068 · 1,246 participants · Start Sep 27, 2018 · Primary completion Jun 1, 2026
Drug: Durvalumab; Tremelimumab and 2 more · For: Unresectable Locally Advanced Urothelial Cancer; Metastatic Urothelial Cancer
Sites: Birmingham, Alabama; Bakersfield, California; Fullerton, California · 222 sites in all
- Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular CarcinomaPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT06921785 · 1,220 participants (planned) · Start May 6, 2025 · Primary completion Mar 15, 2030
Drug: Tremelimumab; Rilvegostomig and 2 more · For: Hepatocellular Carcinoma
Sites: Phoenix, Arizona; Tucson, Arizona; Los Angeles, California · 226 sites in all
- Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).Pivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT03164616 · 1,186 participants · Start Jun 1, 2017 · Primary completion Mar 12, 2021
Drug: Durvalumab; Tremelimumab and 5 more · For: Non Small Cell Lung Cancer NSCLC
Sites: Phoenix, Arizona; Bakersfield, California; Santa Monica, California · 175 sites in all
- Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial CancerPivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT02516241 · 1,126 participants · Start Nov 2, 2015 · Primary completion Jan 27, 2020
Drug: MEDI4736 (Durvalumab); Tremelimumab and 3 more · For: Urothelial Cancer
Sites: Los Angeles, California; Stanford, California; Aurora, Colorado · 222 sites in all
- Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)Pivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT02453282 · 1,118 participants · Start Jul 21, 2015 · Primary completion Oct 4, 2018
Drug: MEDI4736 (Durvalumab); MEDI4736 (Durvalumab)+Tremelimumab and 6 more · For: Non-Small-Cell Lung Carcinoma NSCLC
Sites: Scottsdale, Arizona; Tucson, Arizona; Yuma, Arizona · 196 sites in all
- Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)Pivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT03043872 · 987 participants · Start Mar 27, 2017 · Primary completion Jan 27, 2020
Drug: Durvalumab; Tremelimumab and 3 more · For: Small Cell Lung Carcinoma Extensive Disease
Sites: Birmingham, Alabama; Scottsdale, Arizona; Rogers, Arkansas · 207 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death412
- diarrhoea301
- malignant neoplasm progression294
- pyrexia228
- colitis194
- cytokine release syndrome175
- immune-mediated enterocolitis159
- rash151
- liver disorder133
- pneumonia124
- pneumonitis103
- myocarditis100
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2007 | 3 |
| 2008 | 6 |
| 2009 | 2 |
| 2012 | 1 |
| 2014 | 4 |
| 2015 | 7 |
| 2016 | 40 |
| 2017 | 409 |
| 2018 | 405 |
| 2019 | 86 |
| 2020 | 106 |
| 2021 | 87 |
| 2022 | 76 |
| 2023 | 516 |
| 2024 | 966 |
| 2025 | 966 |
| 2026 | 748 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Imjudo (Tremelimumab-Actl)
2024 spending
$2.8M
Beneficiaries
70
81 claims
Per beneficiary
$39,362
$2,630.52 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $2,386,437 |
| 2024 | $2,755,354 |
Part B: Imjudo (Tremelimumab-Actl) · HCPCS J9347
2024 spending
$48.5M
Beneficiaries
1,259
1,718 claims
Per beneficiary
$38,527
2024 ASP limit $135.71 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $19,156,122 |
| 2024 | $48,504,943 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer.
Cheng Y, Spigel DR, Cho BC, et al. · N Engl J Med 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma.
Abou-Alfa GK, Lau G, Kudo M, et al. · NEJM Evid 2022 · Randomized Controlled Trial, Clinical Trial, Phase III
- Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.
Wang DY, Salem JE, Cohen JV, et al. · JAMA Oncol 2018 · Meta-Analysis, Systematic Review
- Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
Paz-Ares L, Dvorkin M, Chen Y, et al. · Lancet 2019 · Clinical Trial, Phase III, Multicenter Study
- Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study.
Johnson ML, Cho BC, Luft A, et al. · J Clin Oncol 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC.
Rimassa L, Chan SL, Sangro B, et al. · J Hepatol 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
Sponsor: AstraZeneca
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.